CCX 915

Drug Profile

CCX 915

Alternative Names: CCX915

Latest Information Update: 23 Feb 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ChemoCentryx
  • Class Small molecules
  • Mechanism of Action CCR2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammation; Multiple sclerosis

Most Recent Events

  • 01 Dec 2006 Discontinued - Phase-I for Multiple sclerosis in USA (PO)
  • 01 Dec 2006 Discontinued - Preclinical for Inflammation in USA (PO)
  • 01 May 2006 ChemoCentryx completes a phase I trial in Multiple sclerosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top